Drug Profile
Research programme: scanning unnatural protease resistant peptides - EvoRx
Alternative Names: EVO-004; SUPR 4; SUPR-18FLatest Information Update: 28 Mar 2018
Price :
$50
*
At a glance
- Originator EvoRx
- Developer EvoRx; University of Texas M. D. Anderson Cancer Center
- Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Computer-assisted image interpretation enhancers; Image enhancers; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for preclinical development in Breast-cancer(Diagnosis) in USA (IV)
- 20 Sep 2013 EvoRx receives SBIR grant from National Cancer Institute for scanning unnatural protease resistant peptides development in Breast Cancer (Diagnsosis)
- 01 Jan 2013 Preclinical trials in Breast cancer (Diagnosis) in USA (IV)